US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rapport Therapeutics, Inc.

11.19

+0.05000.45%

Volume:101.12K

Turnover:1.14M

Market Cap:408.41M

PE:-4.08

High:11.72

Open:11.05

Low:10.76

Close:11.14

Loading ...

Overview Company News Filings

Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP)

Stifel Nicolaus Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Completes Enrollment for Phase 2a Trial

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

THOMSON REUTERS

Rapport Therapeutics Inc. Set to Participate in Jefferies Global Healthcare Conference

Rapport Therapeutics Inc. to Host Inaugural Investor and Analyst Day in New York City

Chief Scientific Officer David Bredt Reports Disposal of Common Shares of Rapport Therapeutics Inc

Rapport Therapeutics Reports Q1 2025 Financial Results

Optimistic Buy Rating for Rapport Therapeutics Driven by Promising RAP-219 Developments

Promising Clinical Developments and Strategic Initiatives Drive Buy Rating for Rapport Therapeutics, Inc.

Rapport Therapeutics Inc - Rap-219 Phase 2a Trial Results Expected Q3 2025 - SEC Filing

THOMSON REUTERS

Rapport Therapeutics Q1 EPS $(0.68) Beats $(0.76) Estimate

-Charles River agrees with Elliott to add new directors, review business

Stifel Nicolaus Sticks to Its Buy Rating for Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics initiated with an Outperform at Citizens JMP

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares

Simply Wall St.

Top Executives Make Bold Moves with Major Stock Purchases!

Rapport Therapeutics Reports 2024 Financial Results and Progress

Rapport Therapeutics Q4 2024 GAAP EPS $(0.57) Beats $(0.62) Estimate, Ended the year with $305.3M in cash, cash equivalents, and short-term investments, which is expected to fund operations through the end of 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RAPP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":11.19,"timestamp":1749844800000,"preClose":11.14,"halted":0,"volume":101122,"delay":0,"floatShares":14934120,"shares":36497555,"eps":-2.744216,"marketStatus":"Pre-Mkt","change":0.05,"latestTime":"06-16 05:17:45 EDT","open":11.05,"high":11.7194,"low":10.76,"amount":1141301.224,"amplitude":0.086122,"askPrice":13.37,"askSize":100,"bidPrice":10.24,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.744216,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1750080600000},"marketStatusCode":1,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":11.19,"postHourTrading":{"tag":"盘后","latestPrice":11.19,"preClose":11.19,"latestTime":"17:27 EDT","volume":206,"amount":2310.915,"timestamp":1749850076022},"volumeRatio":0.6902973095214491,"impliedVol":1.3148,"impliedVolPercentile":0.9209},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","floatShares":14934120,"roa":"-22.89%","roe":"-33.14%","lyrEps":-3.775953,"volumeRatio":0.6902973095214491,"shares":36497555,"dividePrice":0,"high":11.7194,"amplitude":0.086122,"preClose":11.14,"low":10.76,"week52Low":6.43,"pbRate":"1.43","week52High":29.74,"institutionHeld":0,"latestPrice":11.19,"eps":-2.744216,"divideRate":0,"volume":101122,"delay":0,"ttmEps":-2.744216,"open":11.05,"prevYearClose":17.74,"prevWeekClose":11.19,"prevMonthClose":8.27,"prevQuarterClose":10.03,"fiveDayClose":12.66,"twentyDayClose":9.755,"sixtyDayClose":9.78},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAPP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540087637","title":"Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2540087637","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540087637?lang=en_us&edition=fundamental","pubTime":"2025-06-03 23:10","pubTimestamp":1748963410,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Tempus AI, Inc. Class A (TEM – Research Report) and Rapport ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-tempus-ai-inc-class-a-tem-and-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-tempus-ai-inc-class-a-tem-and-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4613","BK4141","BK4007","RAPP","BK4611","TEM","LU1861558580.USD","LU1861559042.SGD","NA","BK4121"],"gpt_icon":0},{"id":"2540377569","title":"Stifel Nicolaus Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2540377569","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540377569?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:47","pubTimestamp":1748947679,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis reiterated a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report) yesterday. The company’s shares...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","SF"],"gpt_icon":0},{"id":"2540130847","title":"Rapport Therapeutics Completes Enrollment for Phase 2a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2540130847","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540130847?lang=en_us&edition=fundamental","pubTime":"2025-06-03 04:34","pubTimestamp":1748896471,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ( ($RAPP) ) has shared an announcement. On June 2, 2025, Rapport Therapeutics announced that its Phase 2a trial for RAP-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-completes-enrollment-for-phase-2a-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-completes-enrollment-for-phase-2a-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","BK4007","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2540790248","title":"Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2540790248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540790248?lang=en_us&edition=fundamental","pubTime":"2025-06-03 02:45","pubTimestamp":1748889900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA3GYKNB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2538286468","title":"Rapport Therapeutics Inc. Set to Participate in Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2538286468","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538286468?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:00","pubTimestamp":1748343618,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc., a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders, will participate in the Jefferies Global Healthcare Conference in New York City. The company's management is scheduled for a fireside chat on Wednesday, June 4, 2025, at 10:30 a.m. Eastern Time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL1cJ91Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4112","BK4585","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","IE00B64PRP62.GBP","BK4007","LU2095319765.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2537823709","title":"Rapport Therapeutics Inc. to Host Inaugural Investor and Analyst Day in New York City","url":"https://stock-news.laohu8.com/highlight/detail?id=2537823709","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537823709?lang=en_us&edition=fundamental","pubTime":"2025-05-21 19:00","pubTimestamp":1747825234,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc., a clinical-stage biotechnology company, will host its inaugural Investor and Analyst Day on June 2, 2025, in New York City. The event will focus on the company's clinical programs, highlighting the RAP-219 Phase 2a trial in refractory focal epilepsy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL6yXrnh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","LU2095319765.USD","LU2210149790.SGD","RAPP","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","BK4112","BK4588","LU2210150020.SGD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2536763081","title":"Chief Scientific Officer David Bredt Reports Disposal of Common Shares of Rapport Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2536763081","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536763081?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:31","pubTimestamp":1747686674,"startTime":"0","endTime":"0","summary":"David Bredt, the Chief Scientific Officer of Rapport Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL4gyPmd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2534413079","title":"Rapport Therapeutics Reports Q1 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534413079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534413079?lang=en_us&edition=fundamental","pubTime":"2025-05-10 12:20","pubTimestamp":1746850828,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ( ($RAPP) ) has released its Q1 earnings. Here is a breakdown of the information Rapport Therapeutics, Inc. presented to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-reports-q1-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-reports-q1-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4139","RAPP","BK4007"],"gpt_icon":0},{"id":"2534034157","title":"Optimistic Buy Rating for Rapport Therapeutics Driven by Promising RAP-219 Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2534034157","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534034157?lang=en_us&edition=fundamental","pubTime":"2025-05-09 02:05","pubTimestamp":1746727556,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Joseph Thome has maintained their bullish stance on RAPP stock, giving a Buy rating today. Joseph Thome has given his Buy rating d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-rapport-therapeutics-driven-by-promising-rap-219-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-rapport-therapeutics-driven-by-promising-rap-219-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","LENZ"],"gpt_icon":0},{"id":"2533326091","title":"Promising Clinical Developments and Strategic Initiatives Drive Buy Rating for Rapport Therapeutics, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2533326091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533326091?lang=en_us&edition=fundamental","pubTime":"2025-05-08 22:35","pubTimestamp":1746714923,"startTime":"0","endTime":"0","summary":"Analyst Justin Walsh of JonesTrading reiterated a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report), retaining the price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-clinical-developments-and-strategic-initiatives-drive-buy-rating-for-rapport-therapeutics-inc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-clinical-developments-and-strategic-initiatives-drive-buy-rating-for-rapport-therapeutics-inc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP"],"gpt_icon":0},{"id":"2533185819","title":"Rapport Therapeutics Inc - Rap-219 Phase 2a Trial Results Expected Q3 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2533185819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533185819?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:17","pubTimestamp":1746703077,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG1IU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2533183021","title":"Rapport Therapeutics Q1 EPS $(0.68) Beats $(0.76) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533183021","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533183021?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:15","pubTimestamp":1746702907,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.76) by 10.53 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45281379/rapport-therapeutics-q1-eps-0-68-beats-0-76-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","LENZ"],"gpt_icon":0},{"id":"2533093134","title":"-Charles River agrees with Elliott to add new directors, review business","url":"https://stock-news.laohu8.com/highlight/detail?id=2533093134","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533093134?lang=en_us&edition=fundamental","pubTime":"2025-05-07 22:10","pubTimestamp":1746627051,"startTime":"0","endTime":"0","summary":"UPDATE 1--Charles River agrees with Elliott to add new directors, review businessAdds details on other board members in paragraph 3By Svea Herbst-Bayliss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nL1N3RF0TB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU0310800379.SGD","LU1130305938.SGD","LU1732799900.SGD","LU0882574055.USD","BK4581","LU0912757837.SGD","CRL","LU2089984988.USD","LU2468319806.SGD","BK4550","IE00BSNM7G36.USD","LU0889566641.SGD","LU2087621335.USD","LU0965509283.SGD","LU2133065610.SGD","LU0630314457.HKD","LU1057294990.SGD","LU1880398471.USD","LU0792757196.USD","SG9999015978.USD","ABBV","IE00B3PB1722.GBP","LU0203345920.USD","IE0002141913.USD","LU0320765646.SGD","CAH","LU1267930490.SGD","LU0234572021.USD","LU0234570918.USD","IE0034235071.USD","LU0738911758.USD","RAPP","BK4559","LU1929549753.HKD","LU0052756011.USD","IE00BWDBJ516.SGD","LU0128525689.USD","IE00B19Z3B42.SGD","LU0661504455.SGD","LU1430597077.USD","LU0612318971.USD","LU1815336091.USD","RIO.UK","LU1989771016.USD","IE00B2B36J28.USD","LU1551013342.USD","SG9999001440.SGD","LU1244550494.USD","LU0114720955.EUR"],"gpt_icon":0},{"id":"2531033733","title":"Stifel Nicolaus Sticks to Its Buy Rating for Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531033733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531033733?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:19","pubTimestamp":1746011968,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis reiterated a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report) today and set a price target of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-rapport-therapeutics-inc-rapp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-rapport-therapeutics-inc-rapp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","SF"],"gpt_icon":0},{"id":"2525579538","title":"Rapport Therapeutics initiated with an Outperform at Citizens JMP","url":"https://stock-news.laohu8.com/highlight/detail?id=2525579538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525579538?lang=en_us&edition=fundamental","pubTime":"2025-04-08 16:56","pubTimestamp":1744102567,"startTime":"0","endTime":"0","summary":"Citizens JMP initiated coverage of Rapport Therapeutics (RAPP) with an Outperform rating and $28 price target Rapport is developing novel precision...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-initiated-with-an-outperform-at-citizens-jmp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-initiated-with-an-outperform-at-citizens-jmp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","LENZ","JMP"],"gpt_icon":0},{"id":"2521462404","title":"Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2521462404","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521462404?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:00","pubTimestamp":1742554800,"startTime":"0","endTime":"0","summary":"BOSTON and SAN DIEGO, March 21, 2025  -- Rapport Therapeutics, Inc.  , a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced two encore poster presentations at the 2025 American Academy of Neurology  Annual Meeting, taking place from April 5 to April 9, 2025, in San Diego, California. The data from these posters was originally presented at the American Epilepsy Society  Annual Meeting in December 2024.The presentations will highlight the company’s ongoing research and development of RAP-219, a clinical-stage AMPA receptor  negative allosteric modulator  currently in Phase 2 development for the treatment of refractory focal epilepsy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rapport-therapeutics-present-data-2025-110000111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4117","AES","BK4105","BK4139","LENZ","RAPP","LU0061475181.USD","LU1093756325.SGD","BK4519","IE0002270589.USD","BK4107","IE00B7SZLL34.SGD","BK4585","LU1093756168.USD","IE00B19Z3581.USD","AAN","BK4178","AFG","IE00B19Z3B42.SGD","BK4588"],"gpt_icon":0},{"id":"2519031674","title":"Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2519031674","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519031674?lang=en_us&edition=fundamental","pubTime":"2025-03-15 20:17","pubTimestamp":1742041039,"startTime":"0","endTime":"0","summary":"Investors who take an interest in Rapport Therapeutics, Inc.  should definitely note that the Chief Financial Officer, Troy Ignelzi, recently paid US$10.10 per share to buy US$101k worth of the stock. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.Check out our latest analysis for Rapport Therapeutics. The Last 12 Months Of Insider Transactions At Rapport Therapeutics. Notably, that recent purchase by Troy Ignelzi is the biggest insider purchase of Rapport Therapeutics shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is US$10.51. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. Happily, the Rapport Thera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-buying-rapport-therapeutics-chief-121719923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RAPP","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2519987815","title":"Top Executives Make Bold Moves with Major Stock Purchases!","url":"https://stock-news.laohu8.com/highlight/detail?id=2519987815","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519987815?lang=en_us&edition=fundamental","pubTime":"2025-03-14 10:09","pubTimestamp":1741918147,"startTime":"0","endTime":"0","summary":"New insider activity at Rapport Therapeutics, Inc. ( ($RAPP) ) has taken place on March 14, 2025. In recent transactions involving Rapport Therapeu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executives-make-bold-moves-with-major-stock-purchases-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executives-make-bold-moves-with-major-stock-purchases-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2518803984","title":"Rapport Therapeutics Reports 2024 Financial Results and Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2518803984","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518803984?lang=en_us&edition=fundamental","pubTime":"2025-03-12 12:14","pubTimestamp":1741752886,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ( ($RAPP) ) has released its Q4 earnings. Here is a breakdown of the information Rapport Therapeutics, Inc. presented to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-reports-2024-financial-results-and-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-reports-2024-financial-results-and-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","LU2065732104.USD","PRGS","BK4007","RAPP","LENZ","BK4139"],"gpt_icon":0},{"id":"2518125097","title":"Rapport Therapeutics Q4 2024 GAAP EPS $(0.57) Beats $(0.62) Estimate, Ended the year with $305.3M in cash, cash equivalents, and short-term investments, which is expected to fund operations through the end of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2518125097","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518125097?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:10","pubTimestamp":1741691409,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.62) by 8.06 percent. This is a 92.88 percent increase over losses of $(8.01) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44242996/rapport-therapeutics-q4-2024-gaap-eps-0-57-beats-0-62-estimate-ended-the-year-with-305-3m-in-cash-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","RAPP"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAPP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"RAPP","fiscalQuarterEnding":"2025/03","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-11","symbol":"RAPP","fiscalQuarterEnding":"2024/12","expectedEps":-0.62,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-0.57},{"market":"US","date":"2024-11-07","symbol":"RAPP","fiscalQuarterEnding":"2024/09","expectedEps":-0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAPP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RAPP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1744171200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RAPP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RAPP","date":"2025-06-13","current":-5.101351,"percent":0.785156,"low":-19.654107,"twenty":-14.342806,"median":-10.416089,"eighty":-4.981023,"high":-3.640031,"avg":-9.954809,"sd":4.313373,"marketCap":406582762},"quantilePoints":[{"date":"2024-06-07","current":-14.341434,"twenty":-13.293406,"median":-11.721364,"eighty":-11.721364,"marketCap":735830305},{"date":"2024-06-14","current":-17.322989,"twenty":-16.966549,"median":-15.024031,"eighty":-12.769392,"marketCap":888807905},{"date":"2024-06-21","current":-15.733266,"twenty":-17.881887,"median":-15.772475,"eighty":-14.348329,"marketCap":807242405},{"date":"2024-06-28","current":-16.581593,"twenty":-17.17471,"median":-16.18238,"eighty":-14.635158,"marketCap":850768389},{"date":"2024-07-05","current":-17.059223,"twenty":-17.829134,"median":-16.431888,"eighty":-15.672154,"marketCap":875274616},{"date":"2024-07-12","current":-18.299635,"twenty":-18.057796,"median":-16.595851,"eighty":-15.733266,"marketCap":938917651},{"date":"2024-07-19","current":-14.343149,"twenty":-18.092899,"median":-16.610109,"eighty":-15.733266,"marketCap":735918314},{"date":"2024-07-26","current":-16.431888,"twenty":-18.057796,"median":-16.50674,"eighty":-14.592658,"marketCap":843087333},{"date":"2024-08-02","current":-15.740395,"twenty":-18.021611,"median":-16.417631,"eighty":-14.614044,"marketCap":807608170},{"date":"2024-08-09","current":-11.062669,"twenty":-17.829134,"median":-16.189509,"eighty":-14.507112,"marketCap":697147270},{"date":"2024-08-16","current":-12.078391,"twenty":-17.822005,"median":-15.897228,"eighty":-14.341434,"marketCap":761156070},{"date":"2024-08-23","current":-12.943207,"twenty":-17.322989,"median":-15.776039,"eighty":-12.769083,"marketCap":815654991},{"date":"2024-08-30","current":-12.623979,"twenty":-17.301602,"median":-15.672154,"eighty":-12.252515,"marketCap":795537939},{"date":"2024-09-06","current":-11.799793,"twenty":-17.107699,"median":-14.956226,"eighty":-12.030797,"marketCap":743599370},{"date":"2024-09-13","current":-11.027844,"twenty":-17.007896,"median":-14.603351,"eighty":-11.813723,"marketCap":694952683},{"date":"2024-09-20","current":-12.322165,"twenty":-16.6871,"median":-14.421566,"eighty":-11.752199,"marketCap":776518182},{"date":"2024-09-27","current":-12.380206,"twenty":-16.587296,"median":-14.342291,"eighty":-11.752199,"marketCap":780175827},{"date":"2024-10-04","current":-12.072587,"twenty":-16.581593,"median":-13.041877,"eighty":-11.742318,"marketCap":760790305},{"date":"2024-10-11","current":-12.798103,"twenty":-16.461829,"median":-12.783593,"eighty":-11.721364,"marketCap":806510876},{"date":"2024-10-18","current":-15.061713,"twenty":-16.461829,"median":-13.041877,"eighty":-11.742318,"marketCap":949159059},{"date":"2024-10-25","current":-14.057599,"twenty":-16.431888,"median":-14.106934,"eighty":-11.752199,"marketCap":885881788},{"date":"2024-11-01","current":-14.289764,"twenty":-16.420482,"median":-14.289764,"eighty":-11.78122,"marketCap":900512371},{"date":"2024-11-08","current":-13.587752,"twenty":-16.360601,"median":-14.196898,"eighty":-11.792828,"marketCap":976225637},{"date":"2024-11-15","current":-10.665545,"twenty":-16.293733,"median":-13.709352,"eighty":-11.752199,"marketCap":766276774},{"date":"2024-11-22","current":-11.755009,"twenty":-16.213426,"median":-13.641207,"eighty":-11.719637,"marketCap":844550392},{"date":"2024-11-29","current":-11.627735,"twenty":-16.188083,"median":-13.405914,"eighty":-11.573511,"marketCap":835406277},{"date":"2024-12-06","current":-10.416089,"twenty":-16.139607,"median":-12.943207,"eighty":-11.450385,"marketCap":748354310},{"date":"2024-12-13","current":-9.555718,"twenty":-15.982774,"median":-12.73716,"eighty":-11.371152,"marketCap":686540097},{"date":"2024-12-20","current":-9.199351,"twenty":-15.858733,"median":-12.415031,"eighty":-11.254059,"marketCap":660936577},{"date":"2024-12-27","current":-9.688083,"twenty":-15.824515,"median":-12.350651,"eighty":-11.045256,"marketCap":696049976},{"date":"2025-01-03","current":-9.917175,"twenty":-15.797425,"median":-12.316361,"eighty":-10.975704,"marketCap":712509382},{"date":"2025-01-10","current":-7.539701,"twenty":-15.740395,"median":-12.304752,"eighty":-10.859002,"marketCap":541697328},{"date":"2025-01-17","current":-6.460419,"twenty":-15.733266,"median":-12.215086,"eighty":-10.644772,"marketCap":464155239},{"date":"2025-01-24","current":-7.076424,"twenty":-15.684376,"median":-12.087097,"eighty":-10.43238,"marketCap":508412752},{"date":"2025-01-31","current":-8.354253,"twenty":-15.597056,"median":-11.915876,"eighty":-10.137105,"marketCap":600219659},{"date":"2025-02-07","current":-8.211706,"twenty":-15.257893,"median":-11.843324,"eighty":-9.686047,"marketCap":589978251},{"date":"2025-02-14","current":-8.094614,"twenty":-15.103195,"median":-11.828814,"eighty":-9.441681,"marketCap":581565666},{"date":"2025-02-21","current":-6.455328,"twenty":-15.070846,"median":-11.799793,"eighty":-9.297098,"marketCap":463789474},{"date":"2025-02-28","current":-5.106225,"twenty":-15.037336,"median":-11.771597,"eighty":-9.077168,"marketCap":366861863},{"date":"2025-03-07","current":-4.373128,"twenty":-15.01412,"median":-11.747556,"eighty":-8.771711,"marketCap":314191765},{"date":"2025-03-14","current":-4.898381,"twenty":-14.977526,"median":-11.717047,"eighty":-8.416363,"marketCap":383577552},{"date":"2025-03-21","current":-4.530187,"twenty":-14.817535,"median":-11.627735,"eighty":-8.164869,"marketCap":354745367},{"date":"2025-03-28","current":-4.68399,"twenty":-14.676319,"median":-11.461087,"eighty":-7.790176,"marketCap":366789191},{"date":"2025-04-04","current":-4.189957,"twenty":-14.640334,"median":-11.410917,"eighty":-7.133443,"marketCap":328102968},{"date":"2025-04-11","current":-4.315796,"twenty":-14.632186,"median":-11.370643,"eighty":-6.989878,"marketCap":337957006},{"date":"2025-04-17","current":-4.730597,"twenty":-14.622599,"median":-11.327444,"eighty":-6.74653,"marketCap":370438835},{"date":"2025-04-25","current":-4.949801,"twenty":-14.60549,"median":-11.189913,"eighty":-6.457364,"marketCap":387604034},{"date":"2025-05-02","current":-5.280719,"twenty":-14.55844,"median":-11.048158,"eighty":-5.528775,"marketCap":413517298},{"date":"2025-05-09","current":-4.693792,"twenty":-14.472894,"median":-10.976093,"eighty":-5.332796,"marketCap":374099938},{"date":"2025-05-16","current":-4.560992,"twenty":-14.4176,"median":-10.940782,"eighty":-5.2164,"marketCap":363515647},{"date":"2025-05-23","current":-5.092192,"twenty":-14.397354,"median":-10.8247,"eighty":-5.097805,"marketCap":405852811},{"date":"2025-05-30","current":-3.896992,"twenty":-14.370288,"median":-10.665545,"eighty":-4.981023,"marketCap":310594193},{"date":"2025-06-06","current":-5.646289,"twenty":-14.346875,"median":-10.527934,"eighty":-4.950803,"marketCap":450014853},{"date":"2025-06-13","current":-5.101351,"twenty":-14.342806,"median":-10.416089,"eighty":-4.981023,"marketCap":406582762}],"updateTime":1750065465704}}}